Alveo Technologies Announces Partner Program and Portal, New Enablement Software Suite, Further Empowering Partners in Co-Development of Advanced Molecular Diagnostics
11.7.2023 16:45:00 EEST | Business Wire | Press release
Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, today launched a web-based partner portal and suite of enablement software tools to further drive innovative partnerships onto the platform to co-develop and commercialize rapid, point of need diagnostic solutions across multiple life sciences industry sectors. Furthermore, its newest partnership with the Fraunhofer Institute for Cell Therapy and Immunology IZI extends the platform into the large animal veterinary sector. The institute belongs to the Fraunhofer-Gesellschaft, the world’s leading applied research organization.
Alveo has developed a rapid, handheld, reusable, and rugged multiplexed platform that pairs advanced molecular assays with cloud-enabled data analytics for highly accurate and sensitive real-time disease, pathogen and contaminant detection, analysis, and diagnosis. It utilizes Alveo’s globally patented loop-mediated isothermal amplification (LAMP) method for the direct electrical sensing of nucleic acid amplification. This portable molecular lab can deliver rapid testing at the point of need, for example, in doctor’s offices for various infectious diseases, in the field for crop testing, or on farms for livestock testing.
“True to our open-platform philosophy toward innovation, and our vision of making advanced molecular testing universally accessible, we are pleased to launch a web portal and software enablement suite that facilitates our current collaborations and opens the door to future partnerships across many new and underserved markets,” says Alveo CEO Shaun Holt. “We aim to work smarter to bring novel, accurate, and affordable molecular diagnostics to the point of need where actionable insights and outcomes can be significantly improved.”
“Alveo’s be.well™ platform is helping to solve some of the world’s toughest challenges in terms of healthcare access, food security, water and sanitation, and with future pandemic prevention measures,” Holt says.
In its mission to enable earlier detection of pathogens at the point of need, leveraging its open-platform approach, Alveo has partnered with companies in multiple industries around the world to co-develop and commercialize rapid molecular testing capabilities. Alveo’s phased partnerships can range from months to years depending upon the complexity and number of applications of interest. Depending on the extent of a partner’s in-house capabilities, Alveo can either complete the entire test development process with market and technical domain expertise from the partner in a Supported Partnership model, or lend its be.well™ expertise to the partner’s own research and development of assays in a Self-sufficient Partnership. The Partnership Portal facilitates collaboration and gives partners access to all research, training, and development resources required to bring a molecular diagnostic to market.
Fraunhofer IZI, based in Germany, is a world leader in the life sciences and with LAMP technology. Using Alveo’s be.well platform, Fraunhofer IZI will design novel assays within the veterinary space drawing on its deep experience in this area.
“We are impressed with the near-limitless possibilities of Alveo’s be.well™ platform and look forward to collaborating to build out their library of tests,” said Dr. Dirk Kuhlmeier, Head of the Diagnostics Department, Fraunhofer Institute of Cell Therapy and Immunology IZI. “Diagnostics is one of the four areas of focus for Fraunhofer Health and moving testing closer to the point of need is a strategic imperative for us.”
Partnership phases include defining the market and product requirements, primer screening and assay development, and transfer of the assay to the be.well™ Cartridge where it is optimized and validated through testing on Alveo’s IMPACT™ data analysis and testing software suite. Clinical trials and/or field studies are then conducted to verify the assay and validate the platform, Alveo develops and launches the be.well™ Mobile App, the partners collaborate on commercialization plans and Alveo manufactures the product.
Fraunhofer IZI joins a roster of commercialization partners including Barbados Investment and Development Corporation (Export Barbados (BIDC)), which brings the Caribbean nation’s top scientists and life sciences leaders into collaboration with Alveo in designing new assays in the areas of infectious disease, agriculture, veterinary, food, medicine, and aquaculture testing. Alveo has also partnered with agricultural sector leaders to design crop- and animal-specific assays to detect and analyze an even broader range of pathogens within the agricultural space, in the field, in real time.
About Alveo
At Alveo, we strive to improve outcomes by making molecular detection and diagnostics universally accessible – whether that means in the home, on the farm, in the clinic, or even within industrial processes. We understand the value of detecting pathogens earlier where decisions and results can be most effective and impactful. Alveo’s be.well™ platform technology encompasses a unique method of nucleic acid amplification coupled with our proprietary direct electrical sensors, enabling improved outcomes across numerous market sectors and verticals at the point of need. Our platform was designed from the bottom up to enable detection and diagnosis of pathogens earlier given its portability, ease of use, robust and rugged design, multiplexing capability, high accuracy, coupled with fast times to result. Cloud connected and Bluetooth enabled, advanced data and analytics are available for reportable diseases, and monitoring and surveilling of new and emerging pathogens. Our aim is to help customers and patients prevent or significantly limit the negative, destructive impact viruses, fungi, bacteria, and other pathogens can have on our planet. In doing so, we are providing actionable insights at lightspeed, improving health outcomes, saving time, reducing cost, and improving yields. With Be.well™, we Know Sooner, Act Faster™.
To learn more, visit https://alveotechnologies.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230711477764/en/
Contact information
Staci Vernick for Alveo Technologies, Inc.
SL Vernick Communications
610-812-6092/svernick@comcast.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom